Fairfield, Bush & Co.
- SEC CIK
- 0001116247
- Latest filing
- Aug 13, 2026
CRSP holding history
CRISPR Therapeutics AG in every 13F filed by Fairfield, Bush & Co., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
CRSP overviewAll 13F holders of CRSPFull Q2 2026 holdings
- Shares (Q4 2024)
- 0
- Sold out in Q4 2024
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 10
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q4 2024 | 0 | $0 | 0.0% | −5,720−100.0% | Sold out | Holders |
| Q3 2024 | 5,720 | $268.7K | 0.2% | −305−5.1% | Reduced | Holders |
| Q2 2024 | 6,025 | $325.4K | 0.2% | +1,000+19.9% | Added | Holders |
| Q1 2024 | 5,025 | $342.5K | 0.2% | +2,850+131.0% | Added | Holders |
| Q4 2023 | 2,175 | $136.2K | 0.1% | +2,175 | New | Holders |
| Q3 2023 | 0 | $0 | 0.0% | −5,150−100.0% | Sold out | Holders |
| Q2 2023 | 5,150 | $289.1K | 0.1% | 00.0% | Unchanged | Holders |
| Q1 2023 | 5,150 | $232.9K | 0.1% | +5,150 | New | Holders |
| Q3 2022 | 0 | $0 | 0.0% | −590−100.0% | Sold out | Holders |
| Q2 2022 | 590 | $36.0K | <0.1% | +590 | New | Holders |
| Q4 2021 | 0 | $0 | 0.0% | −10,450−100.0% | Sold out | Holders |
| Q3 2021 | 10,450 | $1.17M | 0.4% | +3,300+46.2% | Added | Holders |
| Q2 2021 | 7,150 | $1.16M | 0.3% | +1,250+21.2% | Added | Holders |
| Q1 2021 | 5,900 | $719.0K | 0.2% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.